NICE is unable to make a recommendation on avapritinib (Ayvakit) for treating unresectable or metastatic gastrointestinal stromal tumours in adults because Blueprint Medicines did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)